Displaying 231 - 240 of 516
This position statement raises awareness about the risks of off-label use and misuse of testosterone, growth hormone, thyroid hormone, and adrenal supplements. This statement distinguishes off-label hormone use from legitimate use for diagnoses such as male hypogonadism, growth hormone deficiency, hypothyroidism, and adrenal insufficiency.
Read Position Statement
moreThis guideline provides recommendations on identification, screening, assessment, diagnosis, and treatment of a range of individuals with various causes of adult growth-hormone deficiency (GHD) and patients with childhood-onset GHD transitioning to adult care. The guideline summarizes current knowledge about the accuracy of available GH–stimulation tests, safety of recombinant human GH (rhGH) replacement, unapproved uses of rhGH related to sports and aging, and new developments such as long-acting GH preparations that use a variety of technologies to prolong GH action.…
moreCo-sponsored by AACE, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists
This updated guideline is based on an increased number and quality of the best available scientific studies to guide physicians in the clinical care of patients with obesity who undergo surgical and nonsurgical bariatric procedures. This guideline identifies patient candidates for bariatric procedures, discusses which types of bariatric procedures should be offered, outlines management of patients before… more
This guideline provides recommendations to reduce a person's risk of osteoporosis-related fractures and to evaluate, diagnose, and treat osteoporosis in postmenopausal women, based on fracture presence, assessment of fracture risk/probability, measurement of bone mineral density or bone mass, and a patient’s history, among other factors.
Read Guideline
Osteoporosis is a worldwide problem and people with osteoporosis are more likely to fracture their bones. Listen to…
moreAdvanced diabetes technology can potentially assist persons with diabetes to achieve glycemic targets, improve quality of life, reduce burden of care, offer a personalized approach to self-management, and improve the efficiency of clinical decision-making, among other benefits. This guideline provides recommendations on the efficacy and safety of advanced diabetes technology devices for management of persons with diabetes mellitus, metrics used to aide with the assessment of advanced diabetes technology, and standards for implementation of this technology.…
moreThe 2020 algorithm for management of persons with type 2 diabetes includes sections on lifestyle therapy, a complications-centric model for care of persons with overweight/obesity, prediabetes, management of hypertension and dyslipidemia (risk factors for atherosclerotic cardiovascular disease), glucose control with medications, insulin therapy, and a chart summarizing the attributes of each antihyperglycemic class approved by the U.S. Food and Drug Administration through December 2019.
**An updated algorithm is coming in May 2023**
Read Executive Summary
…
moreThis statement provides recommendations from a workshop in Latin America for incorporating transculturalization factors into guidance for management of diabetes (focusing on glycemic control), obesity (focusing on weight loss), thyroid (focusing on thyroid nodule diagnostics), and bone (focusing on postmenopausal osteoporosis) disorders to assist local experts in creating culturally sensitive and easy-to-implement tools for optimizing endocrine care.
Read Position Statement moreRevision Date 07/30/12 The American Association of Clinical Endocrinologists
Policy for the Elimination of Endocrine Healthcare Disparities in the USA
Since its inception, the American Association of Clinical Endocrinologists (AACE) has advocated for the finest in endocrine education and state-of-the-art health care delivery without regard to race, ethnicity, gender, age, country of origin, economic status, lifestyle, sexual orientation or domestic living arrangements. We, the members of AACE, our patients, and our corporate partners represent the…
more
This position statement outlines new terminology and blueprint for a chronic care model with an advanced diagnostic framework for the comprehensive management of obesity. Adiposity-Based Chronic Disease (ABCD) is a new diagnostic term for obesity that explicitly identifies a chronic disease, alludes to a precise pathophysiologic basis, and avoids the stigmata and confusion related to the differential use and multiple meanings of the term “obesity.”
Read Position Statement moreThis consensus statement provides a practical approach for management of patients with immune checkpoint inhibitor (ICI)-mediated endocrinopathies with case scenarios of various clinical manifestations and highlights the role of the endocrinology team in the multidisciplinary management of ICI-induced endocrinopathies. The statement summarizes the use of ICI (anti-CTLA-4, anti-PD1, and anti-PD-L1) therapies; reviews the clinical presentation of ICI-related endocrinopathies; and discusses the diagnosis and management approaches to endocrinopathies related to ICI therapy.…
more
